{"id":"https://genegraph.clinicalgenome.org/r/0a120074-3856-4d71-b984-2280cebfe757v1.0","type":"EvidenceStrengthAssertion","dc:description":"","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/0a120074-3856-4d71-b984-2280cebfe757","GCISnapshot":"https://genegraph.clinicalgenome.org/r/9232b352-a845-4404-8a98-34cb6ad6ff0e","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/9232b352-a845-4404-8a98-34cb6ad6ff0e_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2020-09-01T00:00:00Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/9232b352-a845-4404-8a98-34cb6ad6ff0e_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2018-10-09T16:00:00.000Z","role":"Approver"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9232b352-a845-4404-8a98-34cb6ad6ff0e_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9232b352-a845-4404-8a98-34cb6ad6ff0e_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7e67dc81-5da9-4aa0-980e-2383a27b4516","type":"EvidenceLine","dc:description":"KO mice were embryonic lethal. The conditional KO mice were not fully phenotyped.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2272ef60-7e3e-4024-9665-425b31fef249","type":"Finding","dc:description":"Morphology of the mitochondria were analyzed in the locus coeruleus, which contains noraderenergic neurons. In the conditional KO mice, 30% of the mitochondria showed depletion of the cristae and appeared \"empty,\" >50% of the mitochondria were loosely packed and had swollen cristae, and normal morphology was found in 20%. Similar results were seen in the cerebellum and the PNS. This is consistent with the findings in fibroblasts from patients with the disease, suggesting that HSD10 is required for mitochondrial structural integrity.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20077426","rdfs:label":"HSD17B10 Conditional KO Mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9232b352-a845-4404-8a98-34cb6ad6ff0e_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/55ea71c4-a954-49b3-bb2f-5f29c1a601ed","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a04f21d5-bb33-4049-a2f3-840d279ea4a6","type":"FunctionalAlteration","dc:description":"Mitochondrial morphology was analyzed by EM in fibroblasts derived from patients compred to controls. Control cells showed dense, dark morphology (WT), while Q165H fibroblasts maintained WT morphology in 45% of the mitochondria, 30% intermediate (loosely packed and/or swollen cristae) and 27% depletion of cristae. 65-86% of the mitochondria in D86G and R130C cells displayed an aberrant phenotype.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20077426","rdfs:label":"Mitochondrial organization"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7de156fc-4b14-4073-8546-eb30584b71ca","type":"EvidenceLine","dc:description":"Upgraded since the same results were shown in patient cells.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c7792807-d733-4cff-9a18-48aa29cc569d","type":"FunctionalAlteration","dc:description":"qPCR analysis was used to analyze mitochondrial tRNA processing in knockdown cells. There was a significant increase in almost all unprocessed transcripts from the heavy strand RNA (up to >25-fold).  This was partly rescued by ectopic expression of WT HSD10. HSD10 forms a complex that interacts with mitochondrial tRNAs. Altered  tRNA processing leads to impaired mitochondrial translation, resulting in respiratory chain defects which can be linked to neurodegeneration.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24549042","rdfs:label":"Mitochondrial tRNA processing"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/9232b352-a845-4404-8a98-34cb6ad6ff0e_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3f0810db-fdc5-4d61-998d-531c8d305892","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3136dccb-6d92-4f7a-a2b4-5aa5bf329d3d","type":"Finding","dc:description":"Altered tRNA processing leads to impaired mitochondrial translation, resulting in respiratory chain defects which can be linked to neurodegeneration.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16176262","rdfs:label":"Yang 2005 Function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/adc67bb4-a552-43b3-ae83-bb6631da742a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de76492f-807a-408c-97ad-84e181c00b20","type":"Finding","dc:description":"Immunoblotting analysis showed an abundance in liver, heart and brain. It also localized to mitochondria.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11559359","rdfs:label":"He 2001 Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/9232b352-a845-4404-8a98-34cb6ad6ff0e_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9232b352-a845-4404-8a98-34cb6ad6ff0e_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1c3379c1-5ebf-4522-a2a3-650aea9b7208_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b05b586-28cc-471b-a3c2-945984b07a09","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18996107","rdfs:label":"Patient 5","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"detectionMethod":"PCR and direct sequencing of genomic DNA from whole blood or fibroblasts. 6 exons and intron boundaries.","phenotypeFreeText":"Isquemic lesions in nucleus; MHBD activity 0.25 nmols/mgprot/min (ref 1.4); blood lactate 19  mmol/L (ref 2); 2M3HBA 323 mmol/mol creatine (ref <12); TG 168 mmol/mol creatine (ref <5); elevated EHA.","phenotypes":["obo:HP_0001943","obo:HP_0001903","obo:HP_0002376","obo:HP_0001639","obo:HP_0001250","obo:HP_0001942","obo:HP_0001873","obo:HP_0003256","obo:HP_0001336","obo:HP_0001987","obo:HP_0001410"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1c3379c1-5ebf-4522-a2a3-650aea9b7208_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18996107","allele":{"id":"https://genegraph.clinicalgenome.org/r/56c5988c-c307-481f-b7c3-3b3ec7f00407","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001037811.2(HSD17B10):c.650G>A (p.Arg217Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/496894"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/bd04fab0-406f-4952-a304-6e45bd79a2dc_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Expression of the variant protein in E. coli was similar to wild type, but less soluble and less thermostable.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/60f8666b-dda7-47e9-a024-94acec63fd82","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28888424","rdfs:label":"Index Case 2","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":12,"detectionMethod":"Exons 1-6 and flanking intronic regions.","firstTestingMethod":"PCR","phenotypeFreeText":"Cardiac decomposition at 18 months which led to death at 21 months. Elevated levels of urinary 2-methyl-3-hydroxybutyric acid and triglyglycine.","phenotypes":["obo:HP_0001251","obo:HP_0030148","obo:HP_0001252","obo:HP_0012758","obo:HP_0001344"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/bd04fab0-406f-4952-a304-6e45bd79a2dc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28888424","allele":{"id":"https://genegraph.clinicalgenome.org/r/e1a1547e-4b2b-475f-9908-72c84bbbf7c0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004493.2(HSD17B10):c.34G>C (p.Val12Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA413155616"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No"}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/9232b352-a845-4404-8a98-34cb6ad6ff0e_ad_other_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ebd8e2d9-b6aa-4f80-ae5d-515d2fd095e3_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Heterlogous expression in E. coli showed that the variant led to complete inactivity. MHD activity in cultured skin fibroblasts was 0.6 nmol/min-1/mg-1 (ref 7.1 +/- 0.8).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/48ec1e28-9e34-49f1-bf07-41a5cbcd3a0e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12696021","rdfs:label":"Patient 1","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":2,"detectionMethod":"Amplification from both cDNA and genomic DNA followed by sequencing and RFLP analysis.","phenotypeFreeText":"Elevated lactate (11.6 mmol/L), Severe hypoglycemia (0.17 mmol/L), Mild hyperammonemia (210 μmol/L),   Urinary organic acid analysis at 2 1/2 months revealed marked excretion of tiglylglycine and 2-methyl-3-hydroxybutyrate without elevation of 2-methylacetoacetate, Loss of motor skills at 14 months, intermittent borderline elevations of C5:1-(tiglyl-)carnitine as well as C5-OH-(2-methyl-3-hydroxybutyryl-)carnitine.","phenotypes":["obo:HP_0002474","obo:HP_0001942","obo:HP_0010863","obo:HP_0002333","obo:HP_0000546","obo:HP_0001252","obo:HP_0001263","obo:HP_0002490","obo:HP_0001943","obo:HP_0001266","obo:HP_0000711","obo:HP_0001987","obo:HP_0011097","obo:HP_0003698","obo:HP_0002919","obo:HP_0002151","obo:HP_0002098","obo:HP_0010864","obo:HP_0006892","obo:HP_0000529","obo:HP_0002521"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/ebd8e2d9-b6aa-4f80-ae5d-515d2fd095e3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12696021","allele":{"id":"https://genegraph.clinicalgenome.org/r/1cb55fbb-ba61-4352-b760-77edd0b38592","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001037811.2(HSD17B10):c.388C>T (p.Arg130Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11442"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e876dadf-b8dd-4b38-a361-b3c3c18f5250_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Heterlogous expression in E. coli showed that the variant led to complete inactivity.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e342d334-c9ff-4f6b-bdf7-864cf295bf21","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18996107","rdfs:label":"Patient 2","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":10,"detectionMethod":"PCR and direct sequencing of genomic DNA from whole blood or fibroblasts. 6 exons and intron boundaries.","phenotypeFreeText":"Multi-organ failure; blood lactate 7.6 mmol/L (ref <2); 2M3HBA 49 mmol/mol creatine (ref <12); TG 154 mmol/mol creatine (ref <5); elevated EHA; MHBD activity 0.05 nmols/mgprot/min (ref 1.4).","phenotypes":["obo:HP_0006892","obo:HP_0000817","obo:HP_0000750","obo:HP_0001263","obo:HP_0000252"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e876dadf-b8dd-4b38-a361-b3c3c18f5250_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18996107","allele":{"id":"https://genegraph.clinicalgenome.org/r/1cb55fbb-ba61-4352-b760-77edd0b38592"}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7403db10-63bc-48f8-8abc-347470a34a2b_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Heterlogous expression in E. coli showed that the variant led to complete inactivity. MHD activity in cultured skin fibroblasts was 0.6 nmol/min-1/mg-1 (ref 7.1 +/- 0.8).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f4814402-752a-45e1-ac24-3cc3a2c77343","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12696021","rdfs:label":"Patient 3","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":7,"detectionMethod":"Amplification from both cDNA and genomic DNA followed by sequencing and RFLP analysis.","phenotypeFreeText":"14 months: developmental regression; unable to focus on objects or follow them; elevated 3H2MBA, 3-hydroxyisobutyric acid, 2EHA and TG; severe cerebral atrophy and occipital infarctions at 4.5 years; seizures at 5 years; physical and mental delay at 7 years; concentric hypertrophy of left ventricle.","phenotypes":["obo:HP_0000648","obo:HP_0001686","obo:HP_0006829","obo:HP_0005157","obo:HP_0003698","obo:HP_0002376","obo:HP_0007663","obo:HP_0001146","obo:HP_0001251","obo:HP_0004396","obo:HP_0002344","obo:HP_0011097","obo:HP_0002059","obo:HP_0002151","obo:HP_0031605","obo:HP_0003648","obo:HP_0010864","obo:HP_0002361","obo:HP_0002375","obo:HP_0002572"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7403db10-63bc-48f8-8abc-347470a34a2b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12696021","allele":{"id":"https://genegraph.clinicalgenome.org/r/1cb55fbb-ba61-4352-b760-77edd0b38592"}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/aa1d7994-ce3e-4dd0-b143-1ee6a57fb86c_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Transfection of D86G-mutated HSD17B10 into HSD17B10-null cells failed to rescue apoptosis.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d98d99eb-5262-4f04-ae68-43b87bab3039","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20077426","rdfs:label":"Case 1","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":7,"detectionMethod":"Sequencing of the entire coding region.","phenotypeFreeText":"Developmental delay in first few months of life; 6 months truncal hypotonia, dyskinesia, athetosis, absent head control, nystagmus. Creatine kinase 225 U/l (ref 5-130); lactate up to 5 mM (ref <2.1); increased lactate/pyruvate ratios; elevated 3-hydroxy-2-methylbutyric acid and triglyglycine; MHBD activity in fibroblasts partially reduced 30-70% of normal","phenotypes":["obo:HP_0031605","obo:HP_0001263","obo:HP_0001640","obo:HP_0008936","obo:HP_0100660","obo:HP_0001639","obo:HP_0001250","obo:HP_0000666","obo:HP_0002421","obo:HP_0002305","obo:HP_0002509"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/aa1d7994-ce3e-4dd0-b143-1ee6a57fb86c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20077426","allele":{"id":"https://genegraph.clinicalgenome.org/r/81640703-412d-4d95-a865-29853fb0177c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001037811.2(HSD17B10):c.257A>G (p.Asp86Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/144033"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7ca7bf1a-d286-4860-92dd-0419e82af06f_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d71146c8-e651-4a7c-81d6-1cef83f382de","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22132097","rdfs:label":"Seaver 2011 Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"detectionMethod":"PCR and sequencing of HSD17B10 followed by RFLP analysis.","phenotypeFreeText":"Developmental Regression noted at 2-3 years, unsteady gait at 3-4 years, seizures at 3-4 years, myoclonic jerks added at 6-7 years, Poor eating habits, Down-going toes. HOS10 activity in lymphoblastoid cells was 2.17 mU/mg protein (ref 4.3+/-2).","phenotypes":["obo:HP_0002376","obo:HP_0001336","obo:HP_0002533","obo:HP_0001266","obo:HP_0010841","obo:HP_0001251","obo:HP_0002121","obo:HP_0004305","obo:HP_0011950","obo:HP_0002317","obo:HP_0012547","obo:HP_0010845","obo:HP_0002384","obo:HP_0001250","obo:HP_0000735","obo:HP_0004396","obo:HP_0000729","obo:HP_0001290","obo:HP_0001260","obo:HP_0000587","obo:HP_0100543","obo:HP_0002123","obo:HP_0001263","obo:HP_0002392","obo:HP_0011003","obo:HP_0001508"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7ca7bf1a-d286-4860-92dd-0419e82af06f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22132097","allele":{"id":"https://genegraph.clinicalgenome.org/r/485d17a4-646d-47df-a770-5d4175cab581","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001037811.2(HSD17B10):c.194T>C (p.Val65Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/95101"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e23d9a9a-1a5a-4400-863e-43ef827412ce_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Expression results in E. coli showed absence of enzyme activity (PMID: 16148061).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3452876-935f-4351-b17d-fe0ec602b497","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18996107","rdfs:label":"Patient 1.1","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"detectionMethod":"Genomic DNA from fibroblasts. 6 exons and intron boundaries amplified and sequenced.","phenotypeFreeText":"Blood lactate 8 mmol/L (ref <2); MHBD activity 0.22 nmols/mgprot/min (ref 1.4)","phenotypes":["obo:HP_0008947","obo:HP_0001942","obo:HP_0001640","obo:HP_0000961","obo:HP_0001943"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e23d9a9a-1a5a-4400-863e-43ef827412ce_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18996107","allele":{"id":"https://genegraph.clinicalgenome.org/r/9b8e98a0-2c08-4f25-85fa-7cc3a49cd969","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001037811.2(HSD17B10):c.713A>G (p.Asn238Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11444"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/646d60ab-ea30-42ea-a941-d3e9f51839b4_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Heterlogous expression in E. coli showed that the variant led to complete inactivity. MHD activity in cultured skin fibroblasts was 1.0 nmol/min-1/mg-1 (ref 7.1 +/- 0.8).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c4672f95-58b5-470f-907a-d16f2233e5af","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12696021","rdfs:label":"Patient 2","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":7,"detectionMethod":"Amplification from both cDNA and genomic DNA followed by sequencing and RFLP analysis.","phenotypeFreeText":"Birth weight, length, and head circumference close to 50th percentile, Could not sit alone before 15 months and could not walk alone until 24 months, Only spoke one word at 24 months, Episode of lethargy and enteritis occurred after a protein‐rich and fatty meal, Elevated excretions of 3‐hydroxy‐2‐methylbutyric acid (3H2MBA), 2‐ethylhydracrylic acid (2EHA), and tiglylglycine (TG), 1.7 mmol/L Blood lactate","phenotypes":["obo:HP_0001254","obo:HP_0000750","obo:HP_0012104","obo:HP_0002194","obo:HP_0025336","obo:HP_0001263","obo:HP_0006913","obo:HP_0011179"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/646d60ab-ea30-42ea-a941-d3e9f51839b4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12696021","allele":{"id":"https://genegraph.clinicalgenome.org/r/1cb55fbb-ba61-4352-b760-77edd0b38592"}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d12c2b5b-f0e9-4968-9151-23db49186206_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Expression in E. coli was similar to wild type, but binding to NADH and NAD+ was reduced. HSD17B10 protein product normally forms a complex with MRPP1/2, but the variant resulted in increased dissociation compared to wild type. More points would have been awarded, but the unaffected brother harbors the variant.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c89dde10-55dd-4dfe-a808-a49c9822b707","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28888424","rdfs:label":"Index Case 1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":13,"detectionMethod":"Exons 1-6 and flanking intronic regions.","firstTestingMethod":"PCR","phenotypeFreeText":"Blood glucose 13.88 mmol/L (ref 4.11-5.49); Lactic acid 8.9 mmol/L (ref 0.5-2.2); blood gas analysis 7.373 pH (ref 7.36-7.44); pCO2 27.3 mmHg (ref 35-45); base excess -12.1 mmol (ref -2 to +2); 2-methyl-3-hydroxybutyric acid and triglyglycine elevated in urine; C5:1 acylcarnitine 0.44 umol/L (normal <0.2).","phenotypes":["obo:HP_0002151","obo:HP_0003074","obo:HP_0000961","obo:HP_0012378","obo:HP_0030891","obo:HP_0001945","obo:HP_0010819","obo:HP_0010538","obo:HP_0045045"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/d12c2b5b-f0e9-4968-9151-23db49186206_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28888424","allele":{"id":"https://genegraph.clinicalgenome.org/r/ff83d671-b920-4f3a-b884-b5925155045f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004493.2(HSD17B10):c.526G>A (p.Val176Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA413151503"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/12849a6e-453b-419e-929a-ae36b41b1cf9_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The variant affects HSD10 subunit interactions. In vitro analysis indicated that the mutant protein was unable to catalyze the dehydrogenation of 2-methyl-3-hydroxybutyryl CoA and oxidation of allopregnanolone.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/110b3005-1217-4555-be05-29a71b353fd0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19706438","rdfs:label":"SV","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":6,"detectionMethod":"PCR amplification and sequencing of X chromosome fragment from fibroblast DNA.","phenotypeFreeText":"Normal development until 6 years, post- measles infection when motor skills and school progress deteriorated. Dysarthria, generalized rigidity with dystonic posturing at 15 years. Benzhexol was given at 18 years, resulting in improvement of tremor and dystonia.","phenotypes":["obo:HP_0002376","obo:HP_0000708","obo:HP_0001332","obo:HP_0001288","obo:HP_0001260","obo:HP_0001347"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/12849a6e-453b-419e-929a-ae36b41b1cf9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19706438","allele":{"id":"https://genegraph.clinicalgenome.org/r/b8aff8f5-9658-4137-9878-1681e75fc5f1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001037811.2(HSD17B10):c.718G>C (p.Glu240Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11446"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9e72fe7f-5f84-4813-a88f-829ff2bc6824_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/719b72d0-75cb-4ddd-857e-2be799d4417a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18996107","rdfs:label":"Patient 3","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"detectionMethod":"Genomic DNA from fibroblasts. PCR and sequencing of 6 exons and intron boundaries.","phenotypeFreeText":"Peculiar face. Blood lactate 8.3 mmol/L (ref <2); 2M3HBA 262 mmol/mol creatine (ref  <12); TG 59 mmol/mol creatine (ref <5);  EHA 50 mmol/mol creatine (ref <7);","phenotypes":["obo:HP_0002376","obo:HP_0000256","obo:HP_0001252"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/9e72fe7f-5f84-4813-a88f-829ff2bc6824_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18996107","allele":{"id":"https://genegraph.clinicalgenome.org/r/f71b2033-6e6f-40b3-8d7d-bb03a99ff384","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.53431562G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA413150885"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/a6d044fd-60cb-4c93-badc-6c1884230e5d_proband_score_evidence_line","type":"EvidenceLine","dc:description":"In vitro analysis: no residual activity or cofactor binding.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/329d2c0f-1a92-40d8-90a4-4a4c3d305606","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20077426","rdfs:label":"Case 2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"detectionMethod":"Sequencing of complete coding region.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Early infancy: constipation, poor feeding, and failure to gain weight; creatine kinase 308 U/l (ref 0-200). Head circumference , height and weight less than 0.4 percentile. Low MHBD activity of 0.2 nmol/min/mg (ref 7.3). 3-hydroxy-2-methylbutyric acid 303 nmol/mol creatine and triglyglycine 321 mmol/mol creatine.","phenotypes":["obo:HP_0001508","obo:HP_0011968","obo:HP_0012450"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a6d044fd-60cb-4c93-badc-6c1884230e5d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20077426","allele":{"id":"https://genegraph.clinicalgenome.org/r/cb1c96a5-8e85-48ff-9972-5e3bebe2ab24","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.53431898T>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA413151693"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":5.2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":9.2}],"evidenceStrength":"Definitive","sequence":306,"specifiedBy":"GeneValidityCriteria6","strengthScore":13.2,"subject":{"id":"https://genegraph.clinicalgenome.org/r/kCVfsr9jRog","type":"GeneValidityProposition","disease":"obo:MONDO_0010327","gene":"hgnc:4800","modeOfInheritance":"obo:HP_0001417"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_9232b352-a845-4404-8a98-34cb6ad6ff0e-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}